YY/T 0870.3-2019 PDF English
US$439.00 · In stock · Download in 9 secondsYY/T 0870.3-2019: Test for genotoxicity of medical devices - Part 3: TK gene mutation test using mouse lymphoma cells Delivery: 9 seconds. True-PDF full-copy in English & invoice will be downloaded + auto-delivered via email. See step-by-step procedureStatus: Valid YY/T 0870.3: Evolution and historical versions
| Standard ID | Contents [version] | USD | STEP2 | [PDF] delivery | Name of Chinese Standard | Status |
| YY/T 0870.3-2019 | English | 439 |
Add to Cart
|
4 days
|
Test for genotoxicity of medical devices - Part 3: TK gene mutation test using mouse lymphoma cells
| Valid |
| YY/T 0870.3-2013 | English | 479 |
Add to Cart
|
3 days
|
Test for genotoxicity of medical devices. Part 3: In vitro mammalian cell gene mutation test using mouse lymphoma cells
| Obsolete |
Excerpted PDFs (Download full copy in 9 seconds upon purchase)PDF Preview: YY/T 0870.3-2019
YY/T 0870.3-2019: Test for genotoxicity of medical devices - Part 3: TK gene mutation test using mouse lymphoma cells
---This is an excerpt. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.), auto-downloaded/delivered in 9 seconds, can be purchased online: https://www.ChineseStandard.net/PDF.aspx/YYT0870.3-2019
Test for genotoxicity of medical devices - Part 3. TK gene mutation test using mouse lymphoma cells
ICS 11.040.01
C30
People's Republic of China Pharmaceutical Industry Standard
Replacing YY/T 0870.3-2013
Medical device genotoxicity test - Part 3.
TK gene mutation test in lymphoma cells
Testforgenotoxicityofmedicaldevices-
Part 3. TKgenemutationtestusingmouselymphomacels
Published on.2019-07-24
2020-08-01 implementation
State Drug Administration issued
Foreword
YY/T 0870 "Medical Toxicity Test for Medical Devices" consists of the following components.
--- Part 1. Bacterial back mutation test;
--- Part 2. In vitro mammalian cell chromosome aberration test;
--- Part 3. TK gene mutation test using mouse lymphoma cells;
--- Part 4. Mammalian bone marrow erythrocyte micronucleus test;
--- Part 5. Mammalian bone marrow chromosome aberration test.
This part is the third part of YY/T 0870.
This part is drafted according to the rules given in GB/T 1.1-2009.
This part replaces YY/T 0870.3-2013 "Medical equipment genotoxicity test - Part 3. Body with mouse lymphoma cells
The foreign mammalian gene mutation test, compared with YY/T 0870.3-2013, except for editorial changes, the main technical changes are as follows.
--- Standard name modified to "Determination of genotoxicity of medical devices - Part 3. TK gene mutations using mouse lymphoma cells
test";
--- Added terminology. cloning efficiency (see 3.1); chromosomal cleavage agents (see 3.2); frameshift mutants (see 3.4); mitotic recombination (see
3.5); mutation (see 3.6); phenotypic expression time (see 3.8); suspension growth (see 3.10); relative suspension growth rate (see 3.11);
For total growth (see 3.12); S9 liver homogenate (see 3.13); S9 mixture (see 3.14); untreated control (see 3.15);
--- Added a note to S9 (see Chapter 5);
--- Revised the relevant requirements for cell lines (see 6.1);
--- Revised the relevant steps for spontaneous mutational clearance of cells (see 6.2);
--- Revised the relevant requirements for mycoplasma contamination detection (see 6.3);
--- Revised the relevant requirements for karyotype stability testing (see 6.4);
--- Increased the selection principle of positive controls (see 9.2);
--- Added "untreated control" (see 9.3);
--- Added an overview of the pre-experiment (see 10.1.1);
---Modified the relevant steps of "contact processing" (see 10.1.2);
--- Modified "0 days of plating efficiency (PE0 plate)", changing the plate culture time to 10d ~ 12d (see 10.1.3);
--- Revised the plate culture time, changed to 10d ~ 12d (see 10.2.3.3);
--- Increased the "relative suspension growth rate" (RSG) (see 11.3);
--- Added "Related Total Growth (RTG)" (see 11.4);
--- Removed the "type (4) small colony mutation rate" (see 11.4);
--- Increased "laboratory capabilities" (see 12);
--- Added "historical comparison data" (see 13);
--- Added "negative criteria" (see 14.1);
--- Added "positive judgment criteria" (see 14.2);
--- Added "result evaluation" (see 15);
--- Added background knowledge (see Appendix A).
Please note that some of the contents of this document may involve patents. The issuing organization of this document is not responsible for identifying these patents.
This part is proposed by the State Drug Administration.
This part is under the jurisdiction of the National Technical Committee for Standardization of Medical Device Biology Evaluation (SAC/TC248).
This section drafted by. Shandong Province Medical Device Product Quality Inspection Center, China Food and Drug Testing Institute.
The main drafters of this section. Sun Lingqi, Wang Guowei, Han Qianqian, Shi Jianfeng.
The previous versions of the standards replaced by this section are.
---YY/T 0870.3-2013.
introduction
The test methods for detecting potentially genotoxic substances given in GB/T 16886.3 are issued by the Organisation for Economic Co-operation and Development (OECD).
The methods specified in the Chemical Testing Guide, but these methods are developed for the characteristics of the chemical, and no detailed tests are given.
The steps are therefore not suitable for direct use in the detection of medical devices/materials. This part of YY/T 0870 refers to the basic original OECD test method.
Then, according to the characteristics of the medical device/material, the test method is appropriately modified, and detailed test procedures are specified, which can be used as
Supplementary method standard for genotoxicity test in GB/T 16886.3.
This part of YY/T 0870 refers to OECD490 (2016) "In vitro mammalian cell gene mutation test using TK gene"
And combined with the characteristics of the medical device/material itself, that is, the mouse is induced by the medical device/material with and without the metabolic activation system.
The positive mutation of the lymphoma cell (L5178YTK/-3.7.C) gene was used to evaluate the potential mutagenicity of the test sample.
In this section, cells are selected based on whether the growth ability and the spontaneous mutation rate in the culture solution are stable. In vitro tests are usually required
To activate the system with exogenous metabolism. However, exogenous metabolic activation systems do not fully mimic metabolic conditions in mammals. pH and
Changes in osmotic pressure or higher cytotoxicity of the test sample can lead to false positive results, making the test results incapable of reacting in vivo
Change the real situation. See Appendix A for background information on the TK gene mutation test in the OECD.
Medical device genotoxicity test - Part 3.
TK gene mutation test in lymphoma cells
1 Scope
This section of YY/T 0870 specifies the use of the mouse lymphoma cell line (L5178YTK /-3.7.2C) for medical devices/materials.
Method for in vitro mammalian cell gene mutation assay.
This section applies to the TK gene mutation test using the mouse lymphoma cell line (L5178YTK /-3.7.2C) using the microplate method.
A method of assessing cytotoxicity using both relative survival (RS) and relative total growth (RTG) indicators.
Note 1. In vitro mammalian cell gene mutation test of oral materials can be found in YY/T 0127.17.
Note 2. In vitro mammalian cell gene mutation testing of nanomaterials may require specific revisions to the methods in this section, but this section does not give
description.
2 Normative references
The following documents are indispensable for the application of this document. For dated references, only dated versions apply to this article.
Pieces. For undated references, the latest edition (including all amendments) applies to this document.
GB/T 16886.1 Biological evaluation of medical devices - Part 1. Evaluation and testing in the process of risk management
GB/T 16886.3 Biological evaluation of medical devices - Part 3. Tests for genotoxicity, carcinogenicity and reproductive toxicity
GB/T 16886.12 Biological evaluation of medical devices - Part 12. Sample preparation and reference materials
3 Terms and definitions
The following terms and definitions as defined in GB/T 16886.1, GB/T 16886.3 and GB/T 16886.12 apply to this document.
3.1
Cloning efficiency cloningefficiency
Cells seeded at low density grew to a percentage of countable colonies.
3.2
Chromosome cleavage agent clastogen
Any substance that causes aberrations in the chromosome structure of a cell or organism.
3.3
Forward mutation forwardmutation
Transformation from a prototype (wild type) to a mutant gene mutation can cause changes in enzyme activity and encoded proteins.
3.4
Frameshift mutant frameshiftmutagens
A substance that causes an increase or decrease in single or multiple base pairs in a DNA molecule.
3.5
Mitotic recombination mitoticrecombination
During mitosis, recombination between homologous chromatids may induce DNA double-strand breaks or loss of heterozygosity.
YY/T 0870.3-2019
Test for genotoxicity of medical devices - Part 3. TK gene mutation test using mouse lymphoma cells
ICS 11.040.01
C30
People's Republic of China Pharmaceutical Industry Standard
Replacing YY/T 0870.3-2013
Medical device genotoxicity test - Part 3.
TK gene mutation test in lymphoma cells
Testforgenotoxicityofmedicaldevices-
Part 3. TKgenemutationtestusingmouselymphomacels
Published on.2019-07-24
2020-08-01 implementation
State Drug Administration issued
Foreword
YY/T 0870 "Medical Toxicity Test for Medical Devices" consists of the following components.
--- Part 1. Bacterial back mutation test;
--- Part 2. In vitro mammalian cell chromosome aberration test;
--- Part 3. TK gene mutation test using mouse lymphoma cells;
--- Part 4. Mammalian bone marrow erythrocyte micronucleus test;
--- Part 5. Mammalian bone marrow chromosome aberration test.
This part is the third part of YY/T 0870.
This part is drafted according to the rules given in GB/T 1.1-2009.
This part replaces YY/T 0870.3-2013 "Medical equipment genotoxicity test - Part 3. Body with mouse lymphoma cells
The foreign mammalian gene mutation test, compared with YY/T 0870.3-2013, except for editorial changes, the main technical changes are as follows.
--- Standard name modified to "Determination of genotoxicity of medical devices - Part 3. TK gene mutations using mouse lymphoma cells
test";
--- Added terminology. cloning efficiency (see 3.1); chromosomal cleavage agents (see 3.2); frameshift mutants (see 3.4); mitotic recombination (see
3.5); mutation (see 3.6); phenotypic expression time (see 3.8); suspension growth (see 3.10); relative suspension growth rate (see 3.11);
For total growth (see 3.12); S9 liver homogenate (see 3.13); S9 mixture (see 3.14); untreated control (see 3.15);
--- Added a note to S9 (see Chapter 5);
--- Revised the relevant requirements for cell lines (see 6.1);
--- Revised the relevant steps for spontaneous mutational clearance of cells (see 6.2);
--- Revised the relevant requirements for mycoplasma contamination detection (see 6.3);
--- Revised the relevant requirements for karyotype stability testing (see 6.4);
--- Increased the selection principle of positive controls (see 9.2);
--- Added "untreated control" (see 9.3);
--- Added an overview of the pre-experiment (see 10.1.1);
---Modified the relevant steps of "contact processing" (see 10.1.2);
--- Modified "0 days of plating efficiency (PE0 plate)", changing the plate culture time to 10d ~ 12d (see 10.1.3);
--- Revised the plate culture time, changed to 10d ~ 12d (see 10.2.3.3);
--- Increased the "relative suspension growth rate" (RSG) (see 11.3);
--- Added "Related Total Growth (RTG)" (see 11.4);
--- Removed the "type (4) small colony mutation rate" (see 11.4);
--- Increased "laboratory capabilities" (see 12);
--- Added "historical comparison data" (see 13);
--- Added "negative criteria" (see 14.1);
--- Added "positive judgment criteria" (see 14.2);
--- Added "result evaluation" (see 15);
--- Added background knowledge (see Appendix A).
Please note that some of the contents of this document may involve patents. The issuing organization of this document is not responsible for identifying these patents.
This part is proposed by the State Drug Administration.
This part is under the jurisdiction of the National Technical Committee for Standardization of Medical Device Biology Evaluation (SAC/TC248).
This section drafted by. Shandong Province Medical Device Product Quality Inspection Center, China Food and Drug Testing Institute.
The main drafters of this section. Sun Lingqi, Wang Guowei, Han Qianqian, Shi Jianfeng.
The previous versions of the standards replaced by this section are.
---YY/T 0870.3-2013.
introduction
The test methods for detecting potentially genotoxic substances given in GB/T 16886.3 are issued by the Organisation for Economic Co-operation and Development (OECD).
The methods specified in the Chemical Testing Guide, but these methods are developed for the characteristics of the chemical, and no detailed tests are given.
The steps are therefore not suitable for direct use in the detection of medical devices/materials. This part of YY/T 0870 refers to the basic original OECD test method.
Then, according to the characteristics of the medical device/material, the test method is appropriately modified, and detailed test procedures are specified, which can be used as
Supplementary method standard for genotoxicity test in GB/T 16886.3.
This part of YY/T 0870 refers to OECD490 (2016) "In vitro mammalian cell gene mutation test using TK gene"
And combined with the characteristics of the medical device/material itself, that is, the mouse is induced by the medical device/material with and without the metabolic activation system.
The positive mutation of the lymphoma cell (L5178YTK/-3.7.C) gene was used to evaluate the potential mutagenicity of the test sample.
In this section, cells are selected based on whether the growth ability and the spontaneous mutation rate in the culture solution are stable. In vitro tests are usually required
To activate the system with exogenous metabolism. However, exogenous metabolic activation systems do not fully mimic metabolic conditions in mammals. pH and
Changes in osmotic pressure or higher cytotoxicity of the test sample can lead to false positive results, making the test results incapable of reacting in vivo
Change the real situation. See Appendix A for background information on the TK gene mutation test in the OECD.
Medical device genotoxicity test - Part 3.
TK gene mutation test in lymphoma cells
1 Scope
This section of YY/T 0870 specifies the use of the mouse lymphoma cell line (L5178YTK /-3.7.2C) for medical devices/materials.
Method for in vitro mammalian cell gene mutation assay.
This section applies to the TK gene mutation test using the mouse lymphoma cell line (L5178YTK /-3.7.2C) using the microplate method.
A method of assessing cytotoxicity using both relative survival (RS) and relative total growth (RTG) indicators.
Note 1. In vitro mammalian cell gene mutation test of oral materials can be found in YY/T 0127.17.
Note 2. In vitro mammalian cell gene mutation testing of nanomaterials may require specific revisions to the methods in this section, but this section does not give
description.
2 Normative references
The following documents are indispensable for the application of this document. For dated references, only dated versions apply to this article.
Pieces. For undated references, the latest edition (including all amendments) applies to this document.
GB/T 16886.1 Biological evaluation of medical devices - Part 1. Evaluation and testing in the process of risk management
GB/T 16886.3 Biological evaluation of medical devices - Part 3. Tests for genotoxicity, carcinogenicity and reproductive toxicity
GB/T 16886.12 Biological evaluation of medical devices - Part 12. Sample preparation and reference materials
3 Terms and definitions
The following terms and definitions as defined in GB/T 16886.1, GB/T 16886.3 and GB/T 16886.12 apply to this document.
3.1
Cloning efficiency cloningefficiency
Cells seeded at low density grew to a percentage of countable colonies.
3.2
Chromosome cleavage agent clastogen
Any substance that causes aberrations in the chromosome structure of a cell or organism.
3.3
Forward mutation forwardmutation
Transformation from a prototype (wild type) to a mutant gene mutation can cause changes in enzyme activity and encoded proteins.
3.4
Frameshift mutant frameshiftmutagens
A substance that causes an increase or decrease in single or multiple base pairs in a DNA molecule.
3.5
Mitotic recombination mitoticrecombination
During mitosis, recombination between homologous chromatids may induce DNA double-strand breaks or loss of heterozygosity.
......
Source: Above contents are excerpted from the full-copy PDF -- translated/reviewed by: www.ChineseStandard.net / Wayne Zheng et al.
Tips & Frequently Asked QuestionsQuestion 1: How long will the true-PDF of English version of YY/T 0870.3-2019 be delivered?Answer: The full copy PDF of English version of YY/T 0870.3-2019 can be downloaded in 9 seconds, and it will also be emailed to you in 9 seconds (double mechanisms to ensure the delivery reliably), with PDF-invoice. Question 2: Can I share the purchased PDF of YY/T 0870.3-2019_English with my colleagues?Answer: Yes. The purchased PDF of YY/T 0870.3-2019_English will be deemed to be sold to your employer/organization who actually paid for it, including your colleagues and your employer's intranet. Question 3: Does the price include tax/VAT?Answer: Yes. Our tax invoice, downloaded/delivered in 9 seconds, includes all tax/VAT and complies with 100+ countries' tax regulations (tax exempted in 100+ countries) -- See Avoidance of Double Taxation Agreements (DTAs): List of DTAs signed between Singapore and 100+ countriesQuestion 4: Do you accept my currency other than USD?Answer: Yes. www.ChineseStandard.us -- YY/T 0870.3-2019 -- Click this link and select your country/currency to pay, the exact amount in your currency will be printed on the invoice. Full PDF will also be downloaded/emailed in 9 seconds. Question 5: Should I purchase the latest version YY/T 0870.3-2019?Answer: Yes. Unless special scenarios such as technical constraints or academic study, you should always prioritize to purchase the latest version YY/T 0870.3-2019 even if the enforcement date is in future. Complying with the latest version means that, by default, it also complies with all the earlier versions, technically. How to buy and download a true PDF of English version of YY/T 0870.3-2019?A step-by-step guide to download PDF of YY/T 0870.3-2019_EnglishStep 1: Visit website https://www.ChineseStandard.net (Pay in USD), or https://www.ChineseStandard.us (Pay in any currencies such as Euro, KRW, JPY, AUD).
Step 2: Search keyword "YY/T 0870.3-2019".
Step 3: Click "Add to Cart". If multiple PDFs are required, repeat steps 2 and 3 to add up to 12 PDFs to cart.
Step 4: Select payment option (Via payment agents Stripe or PayPal).
Step 5: Customize Tax Invoice -- Fill up your email etc.
Step 6: Click "Checkout".
Step 7: Make payment by credit card, PayPal, Google Pay etc. After the payment is completed and in 9 seconds, you will receive 2 emails attached with the purchased PDFs and PDF-invoice, respectively.
Step 8: Optional -- Go to download PDF.
Step 9: Optional -- Click Open/Download PDF to download PDFs and invoice.
See screenshots for above steps: Steps 1~3 Steps 4~6 Step 7 Step 8 Step 9
|